Bausch + Lomb Revenue 2021-2024 | BLCO
Bausch + Lomb annual/quarterly revenue history and growth rate from 2021 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Bausch + Lomb revenue for the quarter ending March 31, 2024 was $1.099B, a 18.05% increase year-over-year.
- Bausch + Lomb revenue for the twelve months ending March 31, 2024 was $4.314B, a 13.23% increase year-over-year.
- Bausch + Lomb annual revenue for 2023 was $4.146B, a 10.03% increase from 2022.
- Bausch + Lomb annual revenue for 2022 was $3.768B, a 0.08% increase from 2021.
- Bausch + Lomb annual revenue for 2021 was $3.765B, a 10.35% increase from 2020.
| Bausch + Lomb Annual Revenue (Millions of US $) |
|
|---|---|
| 2023 | $4,146 |
| 2022 | $3,768 |
| 2021 | $3,765 |
| 2020 | $3,412 |
| Bausch + Lomb Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-03-31 | $1,099 |
| 2023-12-31 | $1,173 |
| 2023-09-30 | $1,007 |
| 2023-06-30 | $1,035 |
| 2023-03-31 | $931 |
| 2022-12-31 | $996 |
| 2022-09-30 | $942 |
| 2022-06-30 | $941 |
| 2022-03-31 | $889 |
| 2021-12-31 | $1,001 |
| 2021-09-30 | $949 |
| 2021-06-30 | $934 |
| 2021-03-31 | $881 |
| 2020-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $5.309B | $4.146B |
| Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $124.295B | 15.60 |
| Cencora (COR) | United States | $47.007B | 18.33 |
| ICON (ICLR) | Ireland | $26.068B | 24.61 |
| DiDi Global (DIDIY) | China | $21.483B | 0.00 |
| Avantor (AVTR) | United States | $14.638B | 21.55 |
| CochLear (CHEOY) | Australia | $14.016B | 0.00 |
| Revvity (RVTY) | United States | $13.265B | 23.27 |
| Natera (NTRA) | United States | $13.164B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.413B | 40.84 |
| Viatris (VTRS) | United States | $12.216B | 3.65 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.939B | 0.00 |
| Charles River Laboratories (CRL) | United States | $10.798B | 20.67 |
| Solventum (SOLV) | United States | $9.292B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.560B | 0.00 |
| HealthEquity (HQY) | United States | $7.157B | 45.96 |
| Organon (OGN) | United States | $5.259B | 4.99 |
| Doximity (DOCS) | United States | $5.034B | 35.26 |
| PACS (PACS) | United States | $4.404B | 0.00 |
| Life Times (LTH) | United States | $3.653B | 38.27 |
| Sotera Health (SHC) | United States | $3.278B | 16.08 |
| Surgery Partners (SGRY) | United States | $3.011B | 27.55 |
| GoodRx Holdings (GDRX) | United States | $2.927B | 111.43 |
| Agilon Health (AGL) | United States | $2.612B | 0.00 |
| Progyny (PGNY) | United States | $2.413B | 41.54 |
| NovoCure (NVCR) | Jersey | $2.063B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.019B | 8.00 |
| Premier (PINC) | United States | $1.914B | 8.19 |
| BrightSpring Health Services (BTSG) | United States | $1.785B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.637B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.566B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.356B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.176B | 0.00 | |
| CareDx (CDNA) | United States | $0.728B | 0.00 |
| Embecta (EMBC) | United States | $0.719B | 4.89 |
| GeneDx Holdings (WGS) | United States | $0.703B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.649B | 6.88 |
| InnovAge Holding (INNV) | United States | $0.619B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.594B | 0.00 |
| Enhabit (EHAB) | United States | $0.442B | 44.05 |
| QDM (QDMI) | Hong Kong, SAR China | $0.437B | 11.45 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.432B | 0.00 |
| ModivCare (MODV) | United States | $0.370B | 6.93 |
| Sonida Senior Living (SNDA) | United States | $0.370B | 0.00 |
| DocGo (DCGO) | United States | $0.313B | 17.11 |
| LifeMD (LFMD) | United States | $0.300B | 0.00 |
| Sharecare (SHCR) | United States | $0.281B | 0.00 |
| MultiPlan (MPLN) | United States | $0.247B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.232B | 0.00 |
| Beauty Health (SKIN) | United States | $0.219B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.189B | 0.00 |
| Biodesix (BDSX) | United States | $0.185B | 0.00 |
| So-Young (SY) | China | $0.111B | 53.55 |
| Pono Capital Two (PTWO) | United States | $0.071B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.045B | 0.00 |
| NeueHealth (NEUE) | United States | $0.043B | 5.83 |
| IceCure Medical (ICCM) | Israel | $0.034B | 0.00 |
| Oncology Institute (TOI) | United States | $0.031B | 0.00 |
| Nutex Health (NUTX) | United States | $0.028B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.024B | 0.00 |
| OncoCyte (OCX) | United States | $0.024B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.023B | 0.00 |
| KindlyMD (KDLY) | $0.017B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.016B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.015B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.005B | 0.00 |
| DermTech (DMTK) | United States | $0.004B | 0.00 |
| OpGen (OPGN) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Assure Holdings (IONM) | United States | $0.001B | 0.00 |